Vis enkel innførsel

dc.contributor.authorBerg, Lars Martin
dc.contributor.authorAnkjell, Torun Karina Solheim
dc.contributor.authorSun, Yi-Qian
dc.contributor.authorTrovik, Tordis A
dc.contributor.authorRikardsen, Oddveig G
dc.contributor.authorSjögren, Anders
dc.contributor.authorMoen, Ketil
dc.contributor.authorHellem, Sølve
dc.contributor.authorBugten, Vegard
dc.date.accessioned2020-09-01T09:52:52Z
dc.date.available2020-09-01T09:52:52Z
dc.date.created2020-07-06T10:38:35Z
dc.date.issued2020
dc.identifier.citationInternational Journal of Otolaryngology. 2020, .en_US
dc.identifier.issn1687-9201
dc.identifier.urihttps://hdl.handle.net/11250/2675786
dc.description.abstractIn this randomized controlled trial, patients with non-severe obstructive sleep apnea (OSA) were treated with continuous positive airway pressure (CPAP) or a twin block mandibular advancement splint (MAS). The primary objective was to compare how CPAP and MAS treatments change the health-related quality of life (HRQoL) and self-reported sleep quality of patients after 12 months of treatment. In total, 104 patients were recruited: 55 were allocated to the CPAP-treatment group and 49 to the MAS-treatment group. We used the SF36 questionnaire to evaluate HRQoL and the Pittsburgh Sleep Quality Index (PSQI) to evaluate sleep quality. All patients were included in the intention-to-treat analyses. These analyses showed improvements in the SF36 physical component score (from 48.8 ± 7.6 at baseline to 50.5 ± 8.0 at follow-up, p = 0.03) in the CPAP treatment group and in the mental component score (from 44.9 ± 12.1 to 49.3 ± 9.2, p = 0.009) in the MAS treatment group. The PSQI global score improved in both the CPAP (from 7.7 ± 3.5 to 6.6 ± 2.9, p = 0.006) and the MAS (8.0 ± 3.1 to 6.1 ± 2.6, p < 0.001) treatment group. No difference was found between treatment groups in any of the SF36 scores or PSQI global score at the final follow-up (p > 0.05) in any analysis. The improvement in the SF36 vitality domain moderately correlated to the improvement in the PSQI global score in both groups (CPAP: |r| = 0.47, p < 0.001; MAS: |r| = 0.36, p = 0.01). In the MAS treatment group, we also found a weak correlation between improvements in the SF36 mental component score and PSQI global score (|r| = 0.28, p = 0.05). In conclusion, CPAP and MAS treatments lead to similar improvements in the HRQoL and self-reported sleep quality in non-severe OSA. Improvements in aspects of HRQoL seems to be moderately correlated to the self-reported sleep quality in both CPAP and MAS treatment.en_US
dc.language.isoengen_US
dc.publisherHindawien_US
dc.relation.urihttps://doi.org/10.1155/2020/2856460
dc.rightsNavngivelse 4.0 Internasjonal*
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/deed.no*
dc.subjectSøvnforstyrrelser / søvnproblemer / søvnbesværen_US
dc.subjectSleep Disordersen_US
dc.titleHealth-related quality of life and sleep quality after 12 months of treatment in non-severe obstructive sleep apnea: A randomized clinical trial with Continuous Positive Airway Pressure and Mandibular Advancement Splintsen_US
dc.typePeer revieweden_US
dc.typeJournal articleen_US
dc.description.versionpublishedVersionen_US
dc.subject.nsiVDP::Otorhinolaryngologi: 755en_US
dc.subject.nsiVDP::Otolaryngology: 755en_US
dc.source.pagenumber10en_US
dc.source.journalInternational Journal of Otolaryngologyen_US
dc.identifier.doi10.1155/2020/2856460
dc.identifier.cristin1818683
dc.description.localcodeCopyright © 2020 Lars M. Berg et al. )is is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.en_US
cristin.ispublishedtrue
cristin.fulltextoriginal
cristin.qualitycode1


Tilhørende fil(er)

Thumbnail

Denne innførselen finnes i følgende samling(er)

Vis enkel innførsel

Navngivelse 4.0 Internasjonal
Med mindre annet er angitt, så er denne innførselen lisensiert som Navngivelse 4.0 Internasjonal